Omeros Corporation's stock is down significantly after the European Medicines Agency (EMA) upheld its negative opinion on the marketing authorization for narsoplimab, a key drug for TA-TMA. This decision effectively blocks the drug's commercialization in Europe and leads Omeros to end its compassionate-use program there, shifting focus entirely to the U.S. market.
Omeros Corporation (OMER) is experiencing a significant negative impact due to the European Medicines Agency's (EMA) final rejection of narsoplimab for TA-TMA. This decision eliminates a major potential market for the drug and forces Omeros to discontinue its compassionate-use program in Europe, despite the drug's FDA approval and strong U.S. demand. While the company will now focus solely on the U.S. launch of YARTEMLEA (narsoplimab's brand name), the loss of the European market represents a substantial blow to its global revenue potential and future growth prospects. Traders should consider the long-term implications of this regulatory setback on Omeros's valuation and its ability to expand internationally.